Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi: Aktualizácia 2013

Translated title of the contribution: EULAR recommendations for the managements of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 Update

J. S. Smolen, R. Landewé, F. C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, Kevin Winthrop, M. De Wit, D. Aletaha, N. Betteridge, J. W J Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. CutoloN. Damjanov, J. M W Hazes, M. Kouloumas, T. K. Kvien, X. Mariette, K. Pavelka, P. L C M Van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. L. Scott, T. Sokka-Isler, J. B. Wong, D. Van Der Heijde

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDMARD. Biosimilars are also addressed. These recommendations are intended to inform rheumatologists, patients, national rheumatology societies and other stakeholders about EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. They are based on evidence and expert opinion and intended to improve outcome in patients with RA.

Original languageUndefined
Pages (from-to)1-25
Number of pages25
JournalRheumatologia
Volume28
Issue number1
StatePublished - 2014

Fingerprint

Antirheumatic Agents
Biosimilar Pharmaceuticals
Rheumatic Diseases
Rheumatoid Arthritis
Glucocorticoids
Consensus
Safety
Expert Testimony
Rheumatology
Advisory Committees
Politics
Therapeutics
Decision Making
Tumor Necrosis Factor-alpha
Rheumatologists

Keywords

  • Biological antirheumatic drugs
  • Disease-modifying antirheumatic drugs
  • EULAR recommendations
  • Managements of rheumatoid arthritis
  • Synthetic antirheumatic drugs

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., ... Van Der Heijde, D. (2014). Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi: Aktualizácia 2013. Rheumatologia, 28(1), 1-25.

Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi : Aktualizácia 2013. / Smolen, J. S.; Landewé, R.; Breedveld, F. C.; Buch, M.; Burmester, G.; Dougados, M.; Emery, P.; Gaujoux-Viala, C.; Gossec, L.; Nam, J.; Ramiro, S.; Winthrop, Kevin; De Wit, M.; Aletaha, D.; Betteridge, N.; Bijlsma, J. W J; Boers, M.; Buttgereit, F.; Combe, B.; Cutolo, M.; Damjanov, N.; Hazes, J. M W; Kouloumas, M.; Kvien, T. K.; Mariette, X.; Pavelka, K.; Van Riel, P. L C M; Rubbert-Roth, A.; Scholte-Voshaar, M.; Scott, D. L.; Sokka-Isler, T.; Wong, J. B.; Van Der Heijde, D.

In: Rheumatologia, Vol. 28, No. 1, 2014, p. 1-25.

Research output: Contribution to journalArticle

Smolen, JS, Landewé, R, Breedveld, FC, Buch, M, Burmester, G, Dougados, M, Emery, P, Gaujoux-Viala, C, Gossec, L, Nam, J, Ramiro, S, Winthrop, K, De Wit, M, Aletaha, D, Betteridge, N, Bijlsma, JWJ, Boers, M, Buttgereit, F, Combe, B, Cutolo, M, Damjanov, N, Hazes, JMW, Kouloumas, M, Kvien, TK, Mariette, X, Pavelka, K, Van Riel, PLCM, Rubbert-Roth, A, Scholte-Voshaar, M, Scott, DL, Sokka-Isler, T, Wong, JB & Van Der Heijde, D 2014, 'Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi: Aktualizácia 2013', Rheumatologia, vol. 28, no. 1, pp. 1-25.
Smolen, J. S. ; Landewé, R. ; Breedveld, F. C. ; Buch, M. ; Burmester, G. ; Dougados, M. ; Emery, P. ; Gaujoux-Viala, C. ; Gossec, L. ; Nam, J. ; Ramiro, S. ; Winthrop, Kevin ; De Wit, M. ; Aletaha, D. ; Betteridge, N. ; Bijlsma, J. W J ; Boers, M. ; Buttgereit, F. ; Combe, B. ; Cutolo, M. ; Damjanov, N. ; Hazes, J. M W ; Kouloumas, M. ; Kvien, T. K. ; Mariette, X. ; Pavelka, K. ; Van Riel, P. L C M ; Rubbert-Roth, A. ; Scholte-Voshaar, M. ; Scott, D. L. ; Sokka-Isler, T. ; Wong, J. B. ; Van Der Heijde, D. / Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi : Aktualizácia 2013. In: Rheumatologia. 2014 ; Vol. 28, No. 1. pp. 1-25.
@article{5e0d4d78ad074249a2238bcbc6742eef,
title = "Odpor{\'u}čania EULAR pre manažment reumatoidnej artrit{\'i}dy syntetick{\'y}mi a biologick{\'y}mi ochorenie modifikuj{\'u}cimi antireumatick{\'y}mi liekmi: Aktualiz{\'a}cia 2013",
abstract = "In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDMARD. Biosimilars are also addressed. These recommendations are intended to inform rheumatologists, patients, national rheumatology societies and other stakeholders about EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. They are based on evidence and expert opinion and intended to improve outcome in patients with RA.",
keywords = "Biological antirheumatic drugs, Disease-modifying antirheumatic drugs, EULAR recommendations, Managements of rheumatoid arthritis, Synthetic antirheumatic drugs",
author = "Smolen, {J. S.} and R. Landew{\'e} and Breedveld, {F. C.} and M. Buch and G. Burmester and M. Dougados and P. Emery and C. Gaujoux-Viala and L. Gossec and J. Nam and S. Ramiro and Kevin Winthrop and {De Wit}, M. and D. Aletaha and N. Betteridge and Bijlsma, {J. W J} and M. Boers and F. Buttgereit and B. Combe and M. Cutolo and N. Damjanov and Hazes, {J. M W} and M. Kouloumas and Kvien, {T. K.} and X. Mariette and K. Pavelka and {Van Riel}, {P. L C M} and A. Rubbert-Roth and M. Scholte-Voshaar and Scott, {D. L.} and T. Sokka-Isler and Wong, {J. B.} and {Van Der Heijde}, D.",
year = "2014",
language = "Undefined",
volume = "28",
pages = "1--25",
journal = "Rheumatologia",
issn = "1210-1931",
publisher = "Termedia Publishing House Ltd.",
number = "1",

}

TY - JOUR

T1 - Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi

T2 - Aktualizácia 2013

AU - Smolen, J. S.

AU - Landewé, R.

AU - Breedveld, F. C.

AU - Buch, M.

AU - Burmester, G.

AU - Dougados, M.

AU - Emery, P.

AU - Gaujoux-Viala, C.

AU - Gossec, L.

AU - Nam, J.

AU - Ramiro, S.

AU - Winthrop, Kevin

AU - De Wit, M.

AU - Aletaha, D.

AU - Betteridge, N.

AU - Bijlsma, J. W J

AU - Boers, M.

AU - Buttgereit, F.

AU - Combe, B.

AU - Cutolo, M.

AU - Damjanov, N.

AU - Hazes, J. M W

AU - Kouloumas, M.

AU - Kvien, T. K.

AU - Mariette, X.

AU - Pavelka, K.

AU - Van Riel, P. L C M

AU - Rubbert-Roth, A.

AU - Scholte-Voshaar, M.

AU - Scott, D. L.

AU - Sokka-Isler, T.

AU - Wong, J. B.

AU - Van Der Heijde, D.

PY - 2014

Y1 - 2014

N2 - In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDMARD. Biosimilars are also addressed. These recommendations are intended to inform rheumatologists, patients, national rheumatology societies and other stakeholders about EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. They are based on evidence and expert opinion and intended to improve outcome in patients with RA.

AB - In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen at 3 months). Tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, biosimilars), abatacept, tocilizumab and, under certain circumstances rituximab are essentially considered to have similar efficacy and safety. If the first bDMARD strategy fails, any other bDMARD may be used. The recommendations also address tofacitinib as a targeted sDMARD (tsDMARD), which is recommended, where licensed, after use of at least one bDMARD. Biosimilars are also addressed. These recommendations are intended to inform rheumatologists, patients, national rheumatology societies and other stakeholders about EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. They are based on evidence and expert opinion and intended to improve outcome in patients with RA.

KW - Biological antirheumatic drugs

KW - Disease-modifying antirheumatic drugs

KW - EULAR recommendations

KW - Managements of rheumatoid arthritis

KW - Synthetic antirheumatic drugs

UR - http://www.scopus.com/inward/record.url?scp=84901930157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901930157&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84901930157

VL - 28

SP - 1

EP - 25

JO - Rheumatologia

JF - Rheumatologia

SN - 1210-1931

IS - 1

ER -